KalVista Pharmaceuticals (KALV) Tops Q2 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts KALV Hot Sheet
Join SI Premium – FREE
KalVista Pharmaceuticals (NASDAQ: KALV) reported Q2 EPS of ($0.92), $0.04 better than the analyst estimate of ($0.96). Revenue for the quarter came in at $13.69 million versus the consensus estimate of $7.17 million.
For earnings history and earnings-related data on KalVista Pharmaceuticals (KALV) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Carriage Services (CSV) Misses Q3 EPS by 22c; Offers Guidance
- Exzeo Group, Inc. (XZO) Reports In-Line Q3 EPS
- ITT Inc (ITT) Tops Q3 EPS by 18c ; Offers Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
